Gastric cancer (GC) is the fourth most common cancer and the third most frequent cause of cancer-related death worldwide (723,000 deaths in 2012)[@b1]. Despite improvements in the diagnosis of GC at an early stage and the availability of new anticancer agents, the 5-year survival rate of patients with advanced GC is only 25--30%[@b2]. Increased efforts to eradicate *Helicobacter pylori* in Asian countries are expected to reduce the incidence of GC in the middle or lower gastric tract[@b3][@b4]. In contrast, the incidence of the intestinal type of differentiated GC located in the upper stomach or esophagogastric junction will likely increase worldwide[@b5]. Such tumors have relatively high incidence of hematogenous metastasis than GC in the middle or lower gastric tract. Therefore, effective management of hematogenous metastasis of GC is raised as an important clinical issue that must be resolved urgently. For the first important step to achieve this goal, discovery of sensitive and specific biomarkers for hematogenous metastasis is required to identify patients at high risk.

GC metastasizes through three dominant processes; hematogenous, lymphatic and direct dissemination from the serosal surface. Among them, hematogenous metastasis requires a distinctive multistep process involving vascular invasion, detachment from a primary site, survival of tumor cells in hypoxic portal blood, tissue engraftment, evasion of the hepatic immune system, and colonization[@b6][@b7]. The application of next-generation sequencing technology reveals that an underlying molecular signature of a tumor cell's ability to metastasize varies according to the metastatic process and target organs[@b8][@b9][@b10][@b11]. We hypothesized that metastasis from primary GC via hematogenous route employs a specific mechanism that can be exploited to identify specific biomarkers for hematogenous metastasis of GC.

Therefore, in the present study, we conducted global expression profiling according to the metastatic route to identify molecules specific for hematogenous metastasis and show that the G protein-coupled receptor 155 (*GPR155*) may serve as a candidate biomarker.

Results
=======

Identification of Candidate Marker
----------------------------------

We sought candidate markers according to the following sieving criteria ([Fig. S1](#S1){ref-type="supplementary-material"}). Firstly, this time we targeted molecules with decreased expression levels in GC tissues compared with the corresponding noncancerous mucosal tissues. Secondly, we focused on the ability which had been already got in the primary lesion to metastasize via hematogenous route. Then, we imposed the condition that there were no differences in gene expression in the primary lesion and hepatic metastases. As a result, the transcriptome analysis identified 21 candidate genes related to hematogenous metastasis ([Table 1](#t1){ref-type="table"}). Among them, the largest decrease in expression in GC tissues compared with noncancerous mucosae was that of *GPR155*. G protein-coupled receptor (GPCR) family have been reported to contribute to tumor progression through interactions with cancer-related signaling pathways. However, there are no reports to our knowledge of an association of *GPR155* with GC. Therefore, we focused on *GPR155* in this study.

Expression of GPR155 and Potentially Interacting Molecules
----------------------------------------------------------

Reduced expression of *GPR155* mRNA was detected in all GC cell lines compared with FHs74Int ([Fig. 1A](#f1){ref-type="fig"}). MKN1, MKN45 and N87 are cell lines which were established from hepatic metastasis. *GPR155* mRNA expression was strongly suppressed in MKN45 and N87 cells. Little is known about cancer-related molecules that interact with *GPR155*[@b12]. To address this gap in our knowledge, we conducted PCR array analysis and found that the expression level of *GPR155* mRNA correlated inversely with those of *TWIST1* and *WNT5B* mRNAs ([Fig. 1B](#f1){ref-type="fig"} and [Fig. S2A](#S1){ref-type="supplementary-material"}). The expression levels of *GPR155, TWIST1,* and *WNT5B* were not related to the state of differentiation of GC cell lines ([Fig. S2A](#S1){ref-type="supplementary-material"}). Pathway analysis of AGS cells indicated that inhibition of *GPR155* mRNA expression increased the levels of *p-ERK1/2* and *p-STAT1* by \>50% ([Fig. 1C](#f1){ref-type="fig"} and [Fig. S3](#S1){ref-type="supplementary-material"}).

Analysis of Mechanisms that Inhibit GPR155 Expression
-----------------------------------------------------

We conducted bisulfite sequencing to investigate whether DNA methylation inhibits *GPR155* transcription. Methylation of cytosine residues within the promoter region of *GPR155* was not detected in the GC cell lines or FHs74Int, ([Fig. 1A](#f1){ref-type="fig"} and [Fig. S2B](#S1){ref-type="supplementary-material"}). TaqMan Copy Number Assays for identification of possible regulatory mechanisms of *GPR155* expression other than DNA methylation detected copy number loss in AGS and SC-6-JCK cells but not in FHs74Int cells ([Fig. 1A](#f1){ref-type="fig"}).

Effects of GPR155 Knockdown on GC Cell Activities
-------------------------------------------------

We inhibited *GPR155* mRNA expression by transfecting AGS and MKN1 cells with si*GPR155* ([Fig. S2C](#S1){ref-type="supplementary-material"}) to determine the influence of *GPR155* on cell phenotype and the contribution of *GPR155* to untransfected AGS and MKN1 those expressed relatively high levels of *GPR155*. We evaluated the proliferation, migration, and invasion of AGS and MKN1 cells. *GPR155* knockdown significantly increased cell proliferation on day 7 compared with untransfected and siControl cells both in AGS and MKN1 cells ([Fig. 2A](#f2){ref-type="fig"} and [Fig. S4A](#S1){ref-type="supplementary-material"}). Moreover, the number GC cells invading the matrigel were increased in cells transfected with si*GPR155* both in AGS and MKN1 cells ([Fig. 2B](#f2){ref-type="fig"} and [Fig. S4B](#S1){ref-type="supplementary-material"}). There was no significant change in migration of AGS cells when *GPR155* expression was inhibited ([Fig. 2C](#f2){ref-type="fig"}), whereas the migration ability of MKN1 cells was increased by knockdown of *GPR155* expression ([Fig. S4C](#S1){ref-type="supplementary-material"}).

Diagnostic Performance of GPR155 Expression Levels
--------------------------------------------------

Primary GC tissues expressed significantly lower levels of *GPR155* mRNA compared with the corresponding noncancerous mucosal tissues ([Fig. 3A](#f3){ref-type="fig"}). Even in tissues of patients with Stage I GC, *GPR155* mRNA expression was reduced by approximately 10-fold. *GPR155* mRNA levels in GC tissues were significantly lower in stage IV patients with synchronous hematogenous metastasis compared with those without synchronous hematogenous metastasis. By looking into patients with stage II/III GC, *GPR155* mRNA levels were lower in GC tissues from patients with metachronous hematogenous metastasis compared to those from patients without metachronous hematogenous metastasis, though the difference was not statistically significant ([Fig. 3A](#f3){ref-type="fig"}).

The optimal cut-off value of the *GPR155* mRNA level in GC tissues was determined at 0.0009 having a modest correlation (AUC = 0.684) with synchronous and metachronous hematogenous metastasis by the receiver operating characteristic curve analysis in all 200 GC patients ([Fig. 3B](#f3){ref-type="fig"}). Using this cut-off value, we stratified patients into low *GPR155 (GPR155* \< 0.0009) and high *GPR155 (GPR155* ≥ 0.0009) groups. Analysis of the association between the *GPR155* mRNA level and clinicopathological factors shows that low *GPR155* mRNA levels in GC tissue significantly associated with age ≥ 65 years, male sex, macroscopic type (other than Borrmann type4/5), low T stage, differentiation, expansive growth type, and synchronous hematogenous metastasis (liver n = 11, lung n = 2, bone n = 1 and brain n = 1) ([Table 2](#t2){ref-type="table"}).

The cumulative incidence of hematogenous recurrence was significantly higher in the low *GPR155* group ([Fig. 3C](#f3){ref-type="fig"}), while the incidence of postoperative adjuvant chemotherapy (S-1 monotherapy) was not different between two groups ([Table 2](#t2){ref-type="table"}). Hematogenous recurrences were found at the liver (n = 9), bone (n = 1), brain (n = 1) and ovary (n = 1). Otherwise, there was no significant difference in overall survival between the two groups in all Stages (5-year survival rates, 53% and 59%, respectively). Similarly, in patients with Stage II/III GC with or without hematogenous recurrence with significant differences in *GPR155* mRNA levels, there were no significant differences in overall survival ([Fig. 4B](#f4){ref-type="fig"}) and disease-free survival ([Fig. 4C](#f4){ref-type="fig"}) between the low and high *GPR155* groups. Multivariate analysis identified low *GPR155* mRNA expression levels in GC tissue as an independent predictive factor of synchronous hematogenous metastasis and metachronous hematogenous metastasis after curative gastrectomy (hazard ratio, 5.38; *P* = 0.001), together with CEA \> 5 ng/ml, vessel invasion, and expansive growth ([Table 3](#t3){ref-type="table"}).

Association between Hematogenous Metastasis and *in situ* Expression of GPR155 Protein
--------------------------------------------------------------------------------------

We performed Immunohistochemical (IHC) to verify whether the expression of *GPR155* was significant for diagnosing and predicting hematogenous metastasis. *GPR155* staining intensity in GC tissues was lower compared with the corresponding noncancerous mucosae in most cases. Moreover, lower levels of *GPR155* correlated significantly with synchronous hematogenous metastasis and metachronous hematogenous metastasis that occurred after curative gastrectomy ([Fig. 4A](#f4){ref-type="fig"}). Strong (focal or diffuse) staining TWIST and WNT5B tended to be found in patients with suppressed GPR155 at GC components ([Fig. 5](#f5){ref-type="fig"}).

Discussion
==========

We performed transcriptome analysis to identify hematogenous metastasis-specific biomarkers of GC. Among candidate molecules identified by our transcriptome analysis, the largest difference in expression levels between primary GC tissue and the corresponding noncancerous mucosal was exhibited by *GPR155* mRNA. In contrast, *GPR155* mRNA was expressed at equivalent levels in primary GC and hepatic metastatic lesions. These findings indicate that decreased expression of *GPR155* may reflect the inherent metastatic potential of GC cells in the primary tumor that was not acquired during metastasis via hematogenous route.

*GPR155*, which resides on chromosome 2q31.1, comprises eighteen exons and encodes a 97 kDa protein. *GPR155* is a member of the seven-transmembrane domain of the GPCR family[@b13]. Ligand binding activates the guanine nucleotide exchange factor activity of GPCRs that exchange GDP for GTP on its associated G protein. The Gα subunit bound to GTP dissociates from the Gβ and Gγ subunits to activate intracellular signaling proteins or target proteins directly. Limited information is available on the ligands for GPCRs at present. Huang XP, *et al*. detected some ligands for other GPCR families, GPR68 and GPR65[@b14]. GPCRs mediate diverse physiological processes such as the visual sensing, immune function, cell proliferation, and tumor metastasis[@b15][@b16]. It is therefore not surprising GPCRs represent 30--50% of the targets of currently marketed therapeutic drugs[@b17][@b18][@b19][@b20]. *GPR155* is a unique member of GPCRs and there have been only a few reports on involvement in malignancies, such as follicular type papillary thyroid carcinoma and colorectal cancer[@b21][@b22]. In those earlier studies, *GPR155* was listed in the results of microarray or proteomic analysis, and no data on the function and clinical significance of *GPR155* was presented.

In the present study, qRT-PCR revealed varying levels of *GPR155* mRNA expression level in GC cell lines independent of their differentiation phenotypes. In all GC cell lines tested here, *GPR155* mRNA expression was reduced compared with that of the human intestinal epithelial cell line FHs74Int. To seek for the regulatory mechanisms of *GPR155* transcription, DNA methylation of the CpG island of a promoter region prevents transcription[@b23], and the promoter region of *GPR155* harbors a CpG island; however, we were unable to detect promoter methylation in the genomes of any of the GC cell lines studied here. Therefore, we investigated copy number loss as a possible secondary suppression mechanism. Copy number loss was detected in 20% of the GC cell lines, which suggests the possibility that copy number loss may contribute to the suppression of *GPR155* mRNA expression. However, histone methylation, micro-RNAs, transcription suppressors and RNA editing may contribute to the suppression of *GRP155* expression, and therefore, further investigations are mandatory to elucidate the regulatory mechanisms of *GPR155* expression[@b24][@b25].

As little evidence is available on the oncological roles of *GPR155*, we performed PCR array and cell signaling pathway analyses to identify cancer-related molecules that potentially interact with *GPR155*. Although statistical power was not strong due to number of analyzed cell lines, we detected an inverse correlation between *GPR155* mRNA expression and those of *TWIST1* and *WNT5B* mRNA. *TWIST1* promotes metastasis through its effects on the epithelial-mesenchymal transition and promotes the formation of distant metastasis in GC[@b26][@b27][@b28][@b29]. *WNT5B* is associated with tumor formation and malignant transformation in GC, breast cancer, and squamous cell carcinoma of the head and neck[@b30][@b31][@b32][@b33]. The correlation between the expression of *GPR155* and these molecules suggests that the suppression of *GPR155* expression interferes with oncogenic signaling pathways. To test this hypothesis, we investigated the downstream effect of inhibiting *GPR155* expression on signaling transduction pathways that mediate cell proliferation. We detected increased *p-ERK1/2* and *p-STAT1* compared with controls. Gα subunit are divided into several subtypes, in which there are two major subtypes, Gsα activating adenylyl cyclase (AC) and Giα suppressing AC[@b34]. To date, the type of Gα subunit coupling to GPR155 has not been specified. Our result suggests that the Gα subunit coupling to *GPR155* may be Giα subunit which suppresses AC.

We selected two GC cell lines expressing relatively high *GPR155* mRNA from differentiated type for assays of cell phenotype, AGS having copy number loss and MKN1 established from hepatic metastasis. In both GC cell lines, *GPR155* knockdown led to significant increases in cell proliferation and invasion, indicating that *GPR155* has downstream effect to cancer-related signaling pathways and therefore acts as a tumor suppressor. Studies on the effect of *GPR155* knockdown on apoptosis and the cell cycle may reveal how *GPR155* affects cell proliferation. Using cells cultured under hypoxic conditions or in suspension may reveal how *GPR155* participates in the mechanism of hematogenous metastasis. Further, mouse xenograft models might provide information on tissue engraftment, invasion, and colonization via hematogenous route.

The most important finding of the present study was that *GPR155* expression demonstrated high diagnostic and predictive performance for hematogenous metastasis of GC. *GPR155* mRNA levels in GC tissues were significantly decreased in all stages, including Stage I, compared with the corresponding normal mucosa. While *GPR155* mRNA expression significantly decreased in GC tissue, it decreased further in patients with synchronous hematogenous metastasis compared to those without. These findings indicate that *GPR155* represents a hematogenous metastasis-specific biomarker for GC. Low differentiation, serosal invasion, diffuse type, young age and infiltrating growth are well-known risk factors for peritoneal dissemination[@b35][@b36][@b37][@b38], and vascular invasion, advanced age, differentiation, Borrmann type 1 or 2, expansive growth have been reported to be risk factors for hepatic metastasis, most frequent hematogenous metastasis of GC[@b35][@b36][@b39][@b40]. The clinicopathological factors associated with reduced *GPR155* expression reported here conflict with known risk factors for peritoneal dissemination and are, however, associated with known risk factors for hepatic metastasis. Moreover, multivariate analysis revealed that suppression of *GPR155* mRNA expression was an independent prognostic factor for synchronous hematogenous metastasis and metachronous hematogenous metastasis that occurred after curative gastrectomy. These clinicopathological analyses support the hypothesis that *GPR155* is specifically associated with hematogenous metastasis of GC and that detecting reduced levels of *GPR155* mRNA in primary GC tissue is useful for the diagnosis of synchronous hematogenous metastasis as well as for determining a patient's risk of hematogenous recurrence after curative gastrectomy. On the other hand, lower expression of *GPR155* mRNA in GC tissues was not associated with overall or disease-free survival. Nevertheless, the cumulative incidence of hematogenous recurrence in patients with Stage II/III GC was significantly higher in the low *GPR155* group. This is rational result, because *GPR155* expression level is specific for hematogenous metastasis and survivals are significantly influenced by other metastatic patterns, peritoneal dissemination or distant lymph node metastasis.

Translating our results into clinical practice, physicians can stratify GC patients according to the risk for hematogenous metastasis by performing qRT-PCR or IHC analysis of biopsy or surgical specimens of primary tumor. For patients at high risk of hematogenous metastasis, appropriate management may be provided according to careful preoperative examinations, and postoperative surveillance focusing on hematogenous metastasis will facilitate early detection and therapeutic intervention. These measures will likely contribute to improve the outcomes of patients with GC.

This study has certain limitations. First, this study was limited by the relatively small sample size. The clinical significance and the cut-off value of *GPR155* expression level as a hematogenous metastasis-specific marker of GC should be evaluated in a larger patient cohort. Second, further analyses of putative interacting molecules indicated here are required to identify the molecular mechanisms underlying the biological activities of *GPR155* in patients with GC. Third, enforced expression of *GPR155* is required for further evaluation of the function of *GPR155* in GC. Finally, the mechanism of *GPR155* expression in GC remains to be identified.

Our results indicate that *GPR155* is a biomarker that is useful for the diagnosis and prediction of hematogenous metastasis of patients with GC.

Methods
=======

Transcriptome Analysis
----------------------

Surgically resected specimens of four patients with GC with synchronous hepatic metastasis without metastasis to the peritoneal cavity or distant lymph nodes were subjected to transcriptome analysis. Global expression profiling was conducted using the HiSeq System (Illumina, San Diego, CA, USA) to compare the expression levels of 57,751 genes in primary GC tissues, the corresponding noncancerous adjacent gastric mucosae, and hepatic metastases.

Sample Collection
-----------------

We used GC cell lines, which were obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan) as follows: MKN1, MKN45, MKN74, NUGC2, NUGC3, NUGC4, and SC-6-JCK. The GC cell lines AGS, KATOIII, and N87 were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The human intestinal epithelial cell line FHs74Int (ATCC) served as a nontumorigenic control. Primary GC tissues and corresponding noncancerous mucosal tissues were collected from 200 patients who underwent gastrectomy at Nagoya University Hospital between 2001 and 2014. None of the patients underwent preoperative chemotherapy.

The methods were carried out in accordance with relevant guidelines. The study protocol was approved by the Medical Ethics Committee of the Nagoya University Hospital, protocol No. 2014--0043. Informed consent was obtained from all patients. Written informed consent for the use of clinical samples and data, as required by the Institutional Review Board, was obtained from all patients.

Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction (qRT-PCR) and PCR Array Analysis
-------------------------------------------------------------------------------------------------------

*GPR155* mRNA levels were determined using qRT-PCR. Total RNAs (10 μg) were extracted from GC cell lines, FHs74Int, and 200 pairs of clinical samples and were amplified using *GPR155*-specific primers ([Table 4](#t4){ref-type="table"}). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (TaqMan, GAPDH control reagents, Applied Biosystems, Foster City, CA, USA) was quantified in each sample for standardization ([Table 4](#t4){ref-type="table"}). *GPR155* mRNA expression level was determined as the value of *GPR155* divided by that of GAPDH. The qRT-PCR protocol was performed as previously described[@b41]. To identify genes encoding putative *GPR155*-interacting proteins, we used the Human Epithelial to Mesenchymal Transition (EMT) RT2 Profiler PCR Array (Qiagen, Chatsworth, CA, USA)[@b42].

DNA Methylation Analysis and Copy Number Analysis
-------------------------------------------------

We used CpG Island Searcher software (<http://cpgislands.usc.edu/>)[@b43][@b44] to detect predicted CpG islands in the *GPR155* promoter region (chr2:174486637--174487426). Genomic DNAs of the cell lines were treated with bisulfite, and bisulfite sequence analysis was performed as previously described ([Table 4](#t4){ref-type="table"})[@b45]. Using purified genomic DNA isolated from GC cell lines, DNA copy numbers were determined using TaqMan Copy Number Assays (Applied Biosystems). The assays were as follows: upstream (assay ID: Hs01092594_cn, 175351658 within exon 1), midstream (assay ID: Hs01971174_cn, 175335170 within exon 6), and downstream (assay ID: Mn00059996_cn, 73351855 overlaps intron 14 and exon 14). Copy number alteration in the *GPR155* locus were determined using CopyCaller™ Software (Life Technologies, Carlsbad, CA, USA)^46^.

Inhibition of GPR155 Expression
-------------------------------

Small interfering RNAs (siRNAs) specific for *GPR155* mRNA (si*GPR155*) ([Table 4](#t4){ref-type="table"}) (Hokkaido System Science, Sapporo, Japan) were used to transfect AGS cells. AccuTarget^TM^ Negative Control siRNA Fluorescein-labeled (Cosmo Bio Co. Ltd., Tokyo, Japan) served as a control nontargeting siRNA (siControl). AGS and MKN1 cells were seeded to grow to 60--80% confluence 24 h later and transfected with siRNAs using LipoTrust EX Oligo (Hokkaido System Science) as previously described[@b47]. After 72 h incubation following siRNA transfection, total RNAs and proteins were extracted. For assays of cell phenotype, the transfected cells were treated with EDTA-trypsin.

Cell Signaling Pathway Analysis
-------------------------------

We used the PathScan^®^ Intracellular Signaling Array Kit (Cell Signaling Technology, Beverly, MA, USA), according to the manufacturer's protocol, to investigate the downstream effects of inhibiting *GPR155* expression on cell signaling pathways in AGS cells.

Assays of Cell Phenotype
------------------------

The proliferation of AGS and MKN1 cells transfected with si*GPR155* was evaluated using a Premix WST-1 Cell Proliferation Assay System (Takara Bio Inc., Kusatsu, Japan). Cells (5 × 10^3^ cells per well) were seeded into 96-well plates in DMEM supplemented with 2% FBS. The optical density of each well was measured in six replicates consist of six technical and two biological replicates on days 0, 1, 3, 5, and 7 after seeding. The ability of cells to invade Matrigel was determined using BioCoat Matrigel Invasion Chambers (BD Biosciences, Bedford, MA, USA) according to the manufacturer's protocol. Cells (2.5 × 10^4^ cells per well) were seeded into the upper well of the chamber in serum-free DMEM, and DMEM supplemented with 10% FBS was supplied into the lower well. After an appropriate incubation time (AGS; 48 h, MKN1; 36 h), we used a light microscope to count the cells present on the surface of the membrane in eight randomly selected fields. Migration was determined using a published wound-healing assay[@b48]. Cells (2 × 10^4^ cells per well) were seeded into 12-well plates in serum-free DMEM using the ibidi Culture insert method (ibidi, Martinsried, Germany) to establish wound gaps of a defined width. After 24 h, the insert was removed, and the width of the wound was measured at 100-μm intervals (20 per well, 40× magnification).

Immunohistochemical Analysis
----------------------------

IHC was performed to determine the localization of *GPR155, TWIST1* and *WNT5B* in 32 representative sections of well-preserved GC tissue and 4 representative sections of well-preserved hepatic metastasis. Sections were incubated for 1 h at room temperature with a rabbit polyclonal antibody raised against *GPR155* (sc-137511, Santa Cruz Biotechnology Inc., Dallas, TX, USA) diluted 1:100, a mouse monoclonal antibody raised against *TWIST* (ab175430, Abcam, Cambridge, UK) diluted 1:500 or a rabbit polyclonal antibody raised against *WNT5B* (ab115563, Abcam, Cambridge, UK), diluted 1:200 in Antibody Diluent (Dako, Carpenteria, CA, USA). Antigen-antibody complexes were visualized using liquid 3, 3'-diaminobenzidine (Nichirei, Tokyo, Japan) after a 2 min incubation. To avoid bias, specimens were randomized, coded, and then analyzed by two independent observers who were uninformed of the identities of the samples. Each observer evaluated all specimens at least twice within a given time interval to minimize intraobserver variation. Staining intensity of *GPR155* was categorized to three groups; increased (GC \> non-cancerous component), equivalent and decreased (GC \> non-cancerous component). Staining intensities of *TWIST* and *WNT5B* were scored by proportions of stained cells in GC component as follows; no-staining (0%), minimal (less than 30%), focal (30--60%) and diffuse (more than 60%)[@b49].

Statistical Analysis
--------------------

Differences between the data of two groups were evaluated using the Mann--Whitney test. To divide patients into two groups, a cut-off value was determined according to the receiver operating characteristic curve analysis drawn by data from all 200 GC patients in stage I--IV GC including those with hematogenous metastasis. The χ^2^ test was used to analyze the significance of the association between *GPR155* mRNA expression levels and patients' clinicopathological characteristics, the significance of the association between IHC intensity and the incidences of hematogenous metastasis, and correlations in IHC intensities. Survival rates were calculated using the Kaplan--Meier method, and the differences in survival curves were evaluated using the log-rank test. Predictive factors were evaluated using multivariate analysis. All statistical analyses were performed using JMP 10 software (SAS Institute Inc., Cary, NC). A p value \< 0.05 was considered statistically significant.
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![Analysis of *GPR155* expression and identification of candidate molecules that interact with *GPR155*: assays used indicate downstream effects.\
(**A**) Reduced expression of *GPR155* mRNA was detected in all GC cell lines compared with that of FHs74Int. Copy number loss was detected in AGS and SC-6-JCK cells. Methylation of the promoter region of *GPR155* was not detected. (**B**) PCR array analysis showing that the expression level of *GPR155* mRNA inversely correlated with those of *TWIST1* and *WNT5B* mRNAs. (**C**) Cell signaling pathway analysis of AGS cells indicated that inhibition of *GPR155* mRNA increased the levels of *p-ERK1/2* and *p-STAT1*.](srep42089-f1){#f1}

![Phenotypes of AGS cells transfected with si*GPR155*.\
(**A,B**) Knockdown of *GPR155* expression increased cell proliferation and invasiveness. (**C**) There was no significant change in cell migration.](srep42089-f2){#f2}

![Expression of *GPR155* in clinical samples, and the cumulative incidence of hematogenous recurrence in patients with Stage II/II GC.\
(**A**) Significantly lower levels of *GPR155* mRNA were detected in primary GC tissues compared with the corresponding noncancerous mucosal tissues. Patients with Stage IV GC with synchronous hematogenous metastasis had lower expression levels of *GPR155* mRNA compared with those of patients without hematogenous metastasis. (**B**) The optimal cut-off value of *GPR155* expression was determined at 0.0009. (**C**) The cumulative incidence of hematogenous recurrence was significantly higher in the low *GPR155* group patients with Stage II/III GC. *Abbreviations*: Hem-rec; hematogenous recurrence, Hem; synchronous hematogenous metastasis.](srep42089-f3){#f3}

![IHC analysis of *GPR155* expression in tissues of representative patients with GC and the survival curve of patients with Stage II/III GC.\
(**A**) *GPR155* staining intensity of GC tissues was generally low compared with the corresponding noncancerous mucosae. *GPR155* staining intensity correlated significantly with synchronous and metachronous hematogenous metastasis. (**B**) There was not significant difference in overall survival between low *GPR155* and high *GPR155* groups with Stage II/III GC. (**C**) There was no significant difference in disease-free survival between the low *GPR155* and high *GPR155* groups with Stage II/III GC. *Abbreviations*: T; tumor tissue, N; non-cancerous component, GC; primary gastric cancer tissue, Hem/Hem-rec; hematogenous metastasis/recurrence.](srep42089-f4){#f4}

![Immunohistochemical staining for GPR155, TWIST and WNT5B proteins.\
(**A**) Results in a representative case using tissues from primary GC and hepatic metastasis. (**B**) Correlations in staining patterns between GPR155, TWIST and WNT5B. *Abbreviations*: T; tumor tissue, N; non-cancerous component, GC; primary gastric cancer tissue.](srep42089-f5){#f5}

###### Candidate tumor suppressor genes downregulated in gastric cancer tissues of patients with hepatic metastasis.

  Symbol     GC tissue/Normal   Full name                       Location                        Function         H-meta/GC tissue                
  --------- ------------------ ----------- --------------------------------------------------- ---------- ------------------------------ ------- --------
  GPR155          −4.43         \<0.0001             G protein-coupled receptor 155              2q31.1    Multi-pass membrane protein    0.01    1.0000
  MFSD4           −4.32         \<0.0001    major facilitator superfamily domain containing 4    1q32.1        Membrane transporter       −0.69   0.4659
  HRASLS2         −4.26         \<0.0001                 HRAS-like suppressor 2                 11q12.3          Metabolic enzyme         −1.38   0.1086
  SLC9A4          −3.95         \<0.0001     solute carrier family 9, subfamily A, member 4      2q12.1         Signal transducer         −0.40   0.6221
  ALDH3A1         −3.40         \<0.0001       aldehyde dehydrogenase 3 family, member A1       17p11.2          Metabolic enzyme         −0.95   0.3085
  DPT             −3.22         \<0.0001                      dermatopontin                     1q12-q23   Extracellular matrix protein   −0.12   0.8893
  POU2AF1         −2.93         \<0.0001            POU class 2 associating factor 1            11q23.1        Transcription factor       −1.07   0.0575
  IRF4            −2.92         \<0.0001             interferon regulatory factor 4             6p25-p23       Transcription factor       −0.84   0.2034
  ASAH2           −2.82         \<0.0001           N-acylsphingosine amidohydrolase 2           10q11.21         Metabolic enzyme         0.09    1.0000
  GSTA1           −2.76          0.0002             glutathione S-transferase alpha 1            6p12.1          Metabolic enzyme         1.17    0.0828
  MZB1            −2.71         \<0.0001      marginal zone B and B1 cell-specific protein       5q31.2      Immunoglobulin mediator      −1.19   0.1480
  LIFR            −2.59         \<0.0001        leukemia inhibitory factor receptor alpha       5p13-p12        Cytokine receptor         0.08    0.9059
  AKR1B10         −2.57          0.0002         aldo-keto reductase family 1, member B10          7q33           Metabolic enzyme         0.22    0.8146
  PAIP2B          −2.50          0.0002      poly (A) binding protein interacting protein 2B     2p13.3        Transcription factor       0.70    0.2801
  PIM2            −2.43         \<0.0001      Pim-2 proto-oncogene, serine/threonine kinase     Xp11.23           Protooncogene           −0.26   0.5942
  GPAT3           −2.26          0.0002          glycerol-3-phosphate acyltransferase 3         4q21.23          Metabolic enzyme         1.13    0.0679
  XYLT2           −2.09         \<0.0001                  xylosyltransferase II                 17q21.33         Metabolic enzyme         −0.15   0.7747
  METTL7A         −2.09          0.0002                methyltransferase like 7 A               12q13.12        Methyltransferase         −0.28   0.6188
  FAM46C          −2.03         \<0.0001      family with sequence similarity 46, member C        1p12         Translational factor       −0.28   0.5389
  IL7R            −2.02          0.0002                  interleukin 7 receptor                   5p13          Cytokine receptor         −0.34   0.5839
  BTG2            −1.83          0.0001                   BTG family, member 2                    1q32         Transcription factor       0.78    0.1001

*Abbreviations: GC tissue*: primary gastric cancer tissue, *Normal*: corresponding adjacent normal gastric tissue, *H-meta*: hepatic metastasis tissue.

###### Association between *GPR155* mRNA expression levels and clinicopathological characteristics of 200 patients with gastric cancer.

  Variables                                     Low *GPR155* in GC tissue   High *GPR155* in GC tissue    *P*
  -------------------------------------------- --------------------------- ---------------------------- -------
  Age                                                                                                   
   \<65 years                                              25                           54               0.021
   ≥65 years                                               58                           63                  
  Sex                                                                                                   
   Male                                                    66                           75               0.017
   Female                                                  17                           42                  
  CEA (ng/ml)                                                                                               
   ≤5                                                      62                           93               0.426
   \>5                                                     21                           24                  
  CA19-9 (IU/ml)                                                                                            
   ≤37                                                     60                           96               0.103
   \>37                                                    23                           21                  
  Tumor location                                                                                        
   Entire                                                   7                           12                  
   Upper third                                             19                           25               0.972
   Middle third                                            24                           33                  
   Lower third                                             33                           47                  
  Tumor size (mm)                                                                                           
   \<50                                                    26                           47               0.199
   ≥50                                                     57                           70                  
  Macroscopic type                                                                                      
   Borrmann type 4/5                                        9                           26               0.033
   Others                                                  74                           91                  
  Tumor depth (UICC)                                                                                    
   pT1-3                                                   47                           47               0.021
   pT4                                                     36                           70                  
  Differentiation                                                                                       
   Differentiated                                          39                           35               0.014
   Undifferentiated                                        44                           82                  
  Lymphatic involvement                                                                                 
   Absent                                                  12                           14               0.607
   Present                                                 71                          103                  
  Vessel invasion                                                                                       
   Absent                                                  33                           40               0.421
   Present                                                 50                           77                  
  Infiltrative growth type                                                                              
   Invasive growth                                         22                           56               0.002
   Expansive growth                                        61                           61                  
  Lymph node metastasis                                                                                 
   Absent                                                  22                           35               0.598
   Present                                                 61                           82                  
  Peritoneal lavage cytology                                                                            
   Negative                                                65                           80               0.118
   Positive                                                18                           37                  
  Synchronous hematogenous metastasis                                                                   
   Absent                                                  71                          114               0.002
   Present                                                 12                           3                   
  Synchronous hepatic metastasis                                                                        
   Absent                                                  75                          114               0.031
   Present                                                  8                           3                   
  UICC stage                                                                                            
   I                                                       14                           18                  
   II                                                      12                           21               0.916
   III                                                     26                           34                  
   IV                                                      31                           44                  
  Post-operative chemotherapy (Stage II/III)                                                            
   S-1 adjuvant                                            21                           29               0.809
   None                                                    17                           26                  

^\*^Statistically significant (*P* \< 0.05). *Abbreviations: CEA*, carcinoembryonic antigen; *CA19-9*, carbohydrate antigen 19-9; *UICC,* Union for International Cancer Control.

###### Predictive factors for hematogenous metastasis/recurrence in 200 patients with gastric cancer.

                                 Hem/Hem-rec (−)    Hem/Hem-rec (+)   Univariate   Multivariable                                
  ---------------------------- ------------------- ----------------- ------------ --------------- --------- ------ ------------ -----------
  Age                              \<65 years             73              6            1.59         0.352                             
  ≥65 years                            107                14                                                                    
  Sex                                 Male                123             18           4.17         0.027    2.42   0.55--17.3     0.259
  Female                               57                  2                                                                    
  CEA                               ≤5 ng/ml              144             11           3.27         0.018    3.26   1.03--10.6    0.044\*
  \>5 ng/ml                            36                  9                                                                    
  CA19--9                           ≤37 IU/ml             143             13           2.08         0.159                             
  \>37 IU/ml                           37                  7                                                                    
  Tumor location                   Lower third            71              9             0.8         0.632                             
  Others                               109                11                                                                    
  Tumor size                         \<50 mm              68              5            1.82         0.248                             
  ≥50 mm                               112                15                                                                    
  Macroscopic type              Borrmann type 4/5         35              1            4.59         0.07                              
  Others                               145                20                                                                    
  Tumor depth                         pT1-3               82              12           1.79         0.219                             
  pT4                                  98                  8                                                                    
  Differentiation                Differentiated           63              9            2.27         0.085                             
  Undifferentiated                     117                11                                                                    
  Lymphatic involvement              Absent               25              1            3.06         0.212                             
  Present                              155                19                                                                    
  Vessel invasion                    Absent               72              1            12.7        \<0.001   19.2   3.53--362    \<0.001\*
  Present                              108                19                                                                    
  Infiltrative growth               Invasive              77              1            14.2        \<0.001   7.79   1.32--150     0.021\*
  Expansive                            103                19                                                                    
  Lymph node metastasis              Absent               54              3            2.43         0.136                             
  Present                              126                17                                                                    
  Peritoneal lavage cytology        Negative              127             18           3.76         0.044    3.62   0.77--27.0     0.108
  Positive                             53                  2                                                                    
  *GPR155* expression                  Low                68              15           4.94         0.001    4.24   1.40--14.8    0.010\*
  High                                 112                 5                                                                    

^\*^Statistically significant in multivariate analysis (*P* \< 0.05). *Abbreviations*: Hem/Hem-rec, hematogenous metastasis/recurrence; *HR*, hazard ratio; *CI*, confidence interval; *CEA*, carcinoembryonic antigen; *CA19-9*, carbohydrate antigen 19-9; *UICC,* Union for International Cancer Control.

###### Sequences of Primers and siRNAs.

  Gene                                  Experiment                         Type                          Sequence             Product size
  --------------------------- ------------------------------ --------------------------------- ----------------------------- --------------
  GPR155                                 qRT-PCR                          forward               5′-AGCAAAGCTGGACTATTCCCT-3′      125 bp
  reverse                      5′-GCCACCAAATAAATGTACTGGA-3′                                                                  
  Bisulfite                              forward              5′-TTTTTGTTTTTGTTTTTTAGGTTTG-3′             197 bp             
  sequencing                             reverse              5′-AACTAAAAATAACAATTCTATCTCC-3′                                
  Knockdown                               siRNA                  5′-ACAUCAUAAGAGAUAUUGG-3′                                   
  5′-GUACAAUAGAACAAACACC-3′                                                                                                  
  5′-AUCAAAACUAACAUUCUGG-3′                                                                                                  
  5′-GUAUAUCACAGCUUCACCA-3′                                                                                                  
  GAPDH                                  qRT-PCR                          forward                5′-GAAGGTGAAGGTCGGAGTC-3′       226 bp
  probe                         5′-CAAGCTTCCCGTTCTCAGCC-3′                                                                   
  reverse                       5′-GAAGATGGTGATGGGATTTC-3′                                                                   

*Abbreviations: qRT-PCR*: quantitative real-time reverse-transcription polymerase chain reaction; *siRNA*: small interfering RNA, *bp*: base pair.
